Get started
Author

Steven P. Govek

Observed names: S Govek, S. Govek, S. P. GOVEK, S. P. Govek, Steven Govek, Steven P Govek
OpenAlex ID: A5059378712
Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts
2015 · Andiliy Lai, Mehmet Kahraman, et al. · Journal of Medicinal Chemistry · 261
Catalytic Asymmetric Synthesis of Quaternary Carbon Centers. Exploratory Studies of Intramolecular Heck Reactions of (Z)-α,β-Unsaturated Anilides and Mechanistic Investigations of Asymmetric Heck Reactions Proceeding via Neutral Intermediates
1998 · Atsuyuki Ashimori, Benoit Bachand, et al. · Journal of the American Chemical Society · 187
The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer
2016 · James D Joseph, Beatrice Darimont, et al. · eLife · 126
Total Synthesis of Asperazine
2001 · Steven P. Govek, Larry E. Overman · Journal of the American Chemical Society · 85
Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927
2018 · Mehmet Kahraman, Steven P. Govek, et al. · ACS Medicinal Chemistry Letters · 81
Total synthesis of (+)-asperazine
2007 · Steven P. Govek, Larry E. Overman · Tetrahedron · 74
Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft
2015 · Steven P. Govek, Johnny Y. Nagasawa, et al. · Bioorganic & Medicinal Chemistry Letters · 50
Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer
2018 · Johnny Nagasawa, Steven Govek, et al. · Journal of Medicinal Chemistry · 44
Benzazoles as allosteric potentiators of metabotropic glutamate receptor 2 (mGluR2): Efficacy in an animal model for schizophrenia
2005 · Steven P. Govek, Celine Bonnefous, et al. · Bioorganic & Medicinal Chemistry Letters · 43
Water-soluble PDE4 inhibitors for the treatment of dry eye
2010 · Steven P. Govek, Guy Oshiro, et al. · Bioorganic & Medicinal Chemistry Letters · 24
Synthesis of (+)-Asperazine
2007 · S. P. Govek, L. E. Overman · Synfacts · 15
Selective estrogen receptor degraders with novel structural motifs induce regression in a tamoxifen-resistant breast cancer xenograft
2018 · Steven P. Govek, Celine Bonnefous, et al. · Bioorganic & Medicinal Chemistry Letters · 10
Dipyridyl amines: Potent metabotropic glutamate subtype 5 receptor antagonists
2005 · Theodore M. Kamenecka, Céline Bonnefous, et al. · Bioorganic & Medicinal Chemistry Letters · 8
Correction: The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer
2019 · James D Joseph, Beatrice Darimont, et al. · eLife · 7
Author response: The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer
2016 · James D Joseph, Beatrice Darimont, et al. · eLife · 5
Abstract 1648: Discovery and evolution of orally bioavailable selective estrogen receptor degraders for ER+ breast cancer: From GDC-0810 to GDC-0927
2018 · Mehmet Kahraman, Steven P. Govek, et al. · Cancer Research · 3
M480, a novel non-bile acid FXR agonist, shows improvement across multiple parameters in a diet-induced obese mouse model with biopsy-confirmed NASH
2017 · B. Wagner, D. Brigham, et al. · Journal of Hepatology · 3
Abstract 5053: Discovery of GDC-0810 a novel, non-steroidal selective estrogen receptor degrader with robust activity in pre-clinical models of endocrine-resistant breast cancer
2015 · James Joseph, Steven Govek, et al. · Cancer Research · 1
Abstract 4757: A novel class of selective estrogen receptors degraders regresses tumors in pre-clinical models of endocrine-resistant breast cancer
2014 · James D. Joseph, Beatrice Darimont, et al. · Cancer Research · 1
FXR agonists with sustained systemic rather than transient intestinal exposure are more efficacious in a diet-induced obese non-alcoholic steatohepatitis mouse model
2017 · B. Wagner, D. Brigham, et al. · Journal of Hepatology
Abstract A37: A novel class of selective estrogen receptor degraders display activity in pre-clinical models of ERα+ ovarian cancer
2013 · James D. Joseph, Beatrice Darimont, et al. · Clinical Cancer Research
Abstract P6-04-12: Novel selective estrogen receptors degraders regress tumors in pre-clinical models of endocrine-resistant breast cancer
2012 · JH Hager, B Darimont, et al. · Cancer Research
Abstract A7: A novel class of selective estrogen receptors degraders regresses tumors in pre-clinical models of endocrine-resistant breast cancer
2012 · Beatrice Darimont, Steven Govek, et al. · Clinical Cancer Research
Abstract A4: A novel class of selective ERα degraders acts as full antagonists/ inverse agonists and displays efficacy in pre-clinical models of endocrine-resistant breast cancer and endometrial cancer
2012 · Beatrice Darimont, Ninh Lu, et al. · Clinical Cancer Research
Abstract A133: A novel class of selective estrogen receptor degraders regresses tumors in preclinical models of endocrine-resistant breast cancer.
2011 · Beatrice Darimont, Steven Govek, et al. · Molecular Cancer Therapeutics
Works count: 29
Citation count: 1,028
H-index: 11
I10-index: 12
Year
Topic
Type